<SEC-DOCUMENT>0001193125-24-228382.txt : 20241112
<SEC-HEADER>0001193125-24-228382.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20240930065125
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-24-228382
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240930

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Akari Therapeutics Plc
		CENTRAL INDEX KEY:			0001541157
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				981034922
		STATE OF INCORPORATION:			X0

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		22 BOSTON WHARF ROAD
		STREET 2:		FL 7
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		(646) 350-0702

	MAIL ADDRESS:	
		STREET 1:		22 BOSTON WHARF ROAD
		STREET 2:		FL 7
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Celsus Therapeutics Plc.
		DATE OF NAME CHANGE:	20130621

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Morria Biopharmaceuticals PLC
		DATE OF NAME CHANGE:	20120201
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g882475g0928002238059.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Commerce Square</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2005 Market Street, 32<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philadelphia, PA 19103</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+1 445 207 7800</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;30, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>VIA EDGAR </U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange
Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Office of Life Sciences </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attention: Joshua Gorsky </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Akari Therapeutics, Plc </B></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>File <FONT STYLE="white-space:nowrap">No.&nbsp;333-282127</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr.&nbsp;Gorsky: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter is submitted
by Akari Therapeutics, Plc (the &#147;<B><I>Company</I></B>&#148; or <I>&#147;</I><B><I>we</I></B><I>&#148;</I>) in response to comments from the staff of the Division of Corporation Finance (the &#147;<B><I>Staff</I></B>&#148;) of the Securities
and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) in a letter dated September&nbsp;26, 2024 (the &#147;<B><I>Comment Letter</I></B>&#148;) with respect to the Company&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-282127)</FONT> filed with the Commission on September&nbsp;13, 2024 (the &#147;<B><I>Form <FONT STYLE="white-space:nowrap">S-4</FONT></I></B>&#148;). The
Company is concurrently filing Amendment No.&nbsp;1 to the Form <FONT STYLE="white-space:nowrap">S-4</FONT> (&#147;<B><I>Amendment No.</I></B><B><I></I></B><B><I>&nbsp;1</I></B>&#148;), which includes changes in response to the Staff&#146;s
comments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For your convenience, the Staff&#146;s numbered comments set forth in the Comment Letter have been reproduced in italics herein
with responses immediately following each comment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Form <FONT STYLE="white-space:nowrap">S-4</FONT> </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise the forepart of the joint proxy statement/prospectus to provide sample calculations of the
exchange ratio and per share merger consideration taking into account any material factors and assumptions and include a high and low range. If shareholders will not know the exact exchange ratio or per share merger consideration at the time of the
shareholder votes, please revise to state as much. </I> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response to Comment No.&nbsp;1</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges the Staff&#146;s comment and has revised its disclosure on the first and second pages of the introductory letter to
Akari shareholders, the first and second of the introductory letter to Peak Bio stockholders, and pages 3, 12, 24-25, 28, 135-136, 157-158 and 199-200 of the Form <FONT STYLE="white-space:nowrap">S-4</FONT> to disclose sample calculations of the
exchange ratio taking into account various net cash scenarios of each of Akari and Peak Bio, including high and low ranges. These updated disclosures also expressly state that shareholders will not know the exact exchange ratio or per share merger
consideration at the time of the shareholder votes. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise the forepart of the joint proxy statement/prospectus to prominently disclose, as you do
elsewhere in the registration statement, that the estimated exchange ratio is such that based on the number of Akari ADSs expected to be issued in accordance with the exchange ratio at the consummation of the merger in exchange for the shares of
Peak Bio Common Stock, Peak Bio stockholders would own approximately 48%, and Akari shareholders would own approximately 52% of the combined company following the consummation of the Merger, on a fully diluted basis. </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response to Comment No.&nbsp;2</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges the Staff&#146;s comment and has revised its disclosure on the first and second pages of the introductory letter to
Akari shareholders, the first and second of the introductory letter to Peak Bio stockholders, and pages 3, 12, 24-25, 28, 135-136, 157-158 and 199-200 of the Form <FONT STYLE="white-space:nowrap">S-4</FONT> to disclose prominently that based on the
number of Akari ADSs expected to be issued in accordance with the exchange ratio at the consummation of the merger in exchange for the shares of Peak Bio Common Stock, Peak Bio stockholders would own approximately 48%, and Akari shareholders would
own approximately 52% of the combined company following the consummation of the Merger, on a fully diluted basis. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise the forepart of the joint proxy statement/prospectus to disclose, as you do elsewhere in the
registration statement, that the aggregate consideration to be received by the Peak Bio stockholders is assumed to be $22.6</I><I><U></U></I><I>&nbsp;million.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response to Comment No.&nbsp;3</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges the Staff&#146;s comment and has revised its disclosure on the first and second pages of the introductory letter to
Akari shareholders, the first and second pages of the introductory letter to Peak Bio stockholders, and pages 3, 12, 24-25, 28, 135-136, 157-158 and 199-200 of the Form <FONT STYLE="white-space:nowrap">S-4</FONT> to disclose that the aggregate
consideration to be received by the Peak Bio stockholders is assumed to be $22.6<U></U>&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you should have any questions
regarding the enclosed matters, please contact me at (445) <FONT STYLE="white-space:nowrap">207-7806.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sincerely,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Jennifer L. Porter</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer L. Porter, Esq.</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rachael M. Bushey, Goodwin Procter LLP </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Laura K. Umbrecht, Goodwin Procter LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g882475g0928002238059.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g882475g0928002238059.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O ,@# 2(  A$! Q$!_\0
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-["XY7/7^5%:=% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
